甘李药业：甘精胰岛素注射液等获得埃塞俄比亚药品注册批件

Group 1 - The core point of the article is that Ganli Pharmaceutical has received regulatory approval for its insulin products in Ethiopia, which is a significant milestone for the company [1] Group 2 - Ganli Pharmaceutical announced on January 15 that it received the registration approval for Glargine Insulin Injection and Glargine Insulin Injection Pre-filled Pen from the Ethiopian National Food and Drug Administration [1] - Glargine insulin is a long-acting insulin that is injected subcutaneously once daily, providing a blood sugar-lowering effect that lasts for 24 hours [1] - The characteristics of Glargine insulin include a long duration of action, stable blood concentration without peaks, and smooth blood sugar control [1]